ICVX insider filings
Icosavax, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-02-20. Screen ICVX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ICVX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Icosavax, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-02-20 | 4 | Simpson Adam K. | Code (U): 358,657 · Code (U): 525,044 · Code (U): 129,032 · Code (U): 129,032 · Disposition to issuer (D): 191,449 (derivative) · Disposition to issuer (D): 237,146 (derivative) · +4 more | EDGAR |
| 2024-02-20 | 4 | Khan Amin | Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 180,000 (derivative) | EDGAR |
| 2024-02-20 | 4 | Cearley Cassia | Code (U): 131,799 · Disposition to issuer (D): 2,511 (derivative) · Disposition to issuer (D): 104,204 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 180,474 (derivative) · Disposition to issuer (D): 140,000 (derivative) · +2 more | EDGAR |
| 2024-02-20 | 4 | Wassil Jim | Code (U): 3,695 · Disposition to issuer (D): 7,392 · Disposition to issuer (D): 44,556 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-02-20 | 4 | Russo Thomas Joseph | Code (U): 39,367 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 376,590 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 97,500 (derivative) · Disposition to issuer (D): 74,500 (derivative) | EDGAR |
| 2024-02-20 | 4 | Shiver John W. | Code (U): 8,066 · Disposition to issuer (D): 2,833 · Disposition to issuer (D): 9,643 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 25,500 (derivative) | EDGAR |
| 2024-02-20 | 4 | Kanesa-thasan Niranjan | Code (U): 223,980 · Disposition to issuer (D): 2,511 (derivative) · Disposition to issuer (D): 42,193 (derivative) · Disposition to issuer (D): 82,580 (derivative) · Disposition to issuer (D): 108,369 (derivative) · Disposition to issuer (D): 110,000 (derivative) · +2 more | EDGAR |
| 2024-02-20 | 4 | Veneman Ann M | Code (U): 11,209 · Disposition to issuer (D): 2,834 · Disposition to issuer (D): 22,278 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 25,500 (derivative) | EDGAR |
| 2024-02-20 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director, 10% owner Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Code (U): 5,543 · Code (U): 5,324,897 · Code (U): 638,668 · Disposition to issuer (D): 22,278 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-02-20 | 4 | MCDADE MARK | Code (U): 55,786 · Code (U): 3,510,228 · Disposition to issuer (D): 22,278 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-02-20 | 4 | FIELDS HEIDI | Code (U): 11,376 · Disposition to issuer (D): 2,917 · Disposition to issuer (D): 22,278 (derivative) · Disposition to issuer (D): 25,266 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-02-02 | 4 | Simpson Adam K. — Chief Executive Officer, Director | Gift (G): 6,532 @ $0 · Option exercise (M): 15,000 @ $1.04 · Sale (S): 15,000 @ $15.29 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Simpson Adam K. — Chief Executive Officer, Director | Option exercise (M): 4,789 @ $0.84 · Option exercise (M): 93,227 @ $1.04 · Option exercise (M): 4,789 (derivative) @ $0 · Option exercise (M): 93,227 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Kanesa-thasan Niranjan — Chief Medical Officer | Option exercise (M): 13,806 @ $0.84 · Option exercise (M): 74,648 @ $1.04 · Option exercise (M): 11,947 @ $5.90 · Option exercise (M): 5,972 @ $15 · Sale (S): 106,373 @ $15.70 · Option exercise (M): 13,806 (derivative) @ $0 · +3 more | EDGAR |
| 2024-01-04 | 4 | Simpson Adam K. — Chief Executive Officer, Director | Option exercise (M): 15,000 @ $1.04 · Sale (S): 15,000 @ $15.67 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2023-12-22 | 4 | Simpson Adam K. — Chief Executive Officer, Director | Sale (S): 62,205 @ $15.46 · Option exercise (M): 102,574 @ $1.04 · Option exercise (M): 40,000 @ $2.47 · Option exercise (M): 23,343 @ $0.84 · Sale (S): 50,000 @ $15.44 · Sale (S): 40,000 @ $15.43 · +3 more | EDGAR |
| 2023-12-22 | 4 | Russo Thomas Joseph — Chief Financial Officer | Sale (S): 10,753 @ $15.46 · Sale (S): 4,430 @ $15.46 | EDGAR |
| 2023-12-22 | 4 | Kanesa-thasan Niranjan — Chief Medical Officer | Sale (S): 11,884 @ $15.46 | EDGAR |
| 2023-12-22 | 4 | Cearley Cassia — Chief Business Officer | Sale (S): 7,934 @ $15.46 | EDGAR |
| 2023-12-15 | 4 | Cearley Cassia — Chief Business Officer | Sale (S): 8,759 @ $16.01 | EDGAR |
| 2023-08-01 | 4 | Simpson Adam K. — Chief Executive Officer, Director | Option exercise (M): 3,000 @ $0.84 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2023-08-01 | 4 | Kanesa-thasan Niranjan — Chief Medical Officer | Sale (S): 3,323 @ $8.86 | EDGAR |
| 2023-08-01 | 4 | Simpson Adam K. — Chief Executive Officer, Director | Sale (S): 11,788 @ $8.86 | EDGAR |
| 2023-08-01 | 4 | Russo Thomas Joseph — Chief Financial Officer | Sale (S): 3,066 @ $8.86 | EDGAR |
| 2023-08-01 | 4 | Cearley Cassia — Chief Business Officer | Sale (S): 1,888 @ $8.86 | EDGAR |
| 2023-07-03 | 4 | Holtzman Douglas — Chief Scientific Officer | Option exercise (M): 16,356 @ $1.04 · Sale (S): 14,261 @ $8.74 · Sale (S): 2,095 @ $9.59 · Option exercise (M): 16,356 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Khan Amin — EVP, Head of Research & Dev. | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Wassil Jim — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Shiver John W. — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | Veneman Ann M — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director, 10% owner Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | MCDADE MARK — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | FIELDS HEIDI — Director | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Cearley Cassia — Chief Business Officer | Sale (S): 10,000 @ $10 | EDGAR |
| 2023-04-05 | 4 | Holtzman Douglas — Chief Scientific Officer | Option exercise (M): 20,443 @ $1.04 · Sale (S): 20,143 @ $6.08 · Sale (S): 300 @ $6.56 · Option exercise (M): 20,443 (derivative) @ $0 | EDGAR |
| 2023-03-08 | 4 | Cearley Cassia — Chief Business Officer | Sale (S): 5,000 @ $7.75 | EDGAR |
| 2023-02-17 | 4 | Russo Thomas Joseph — Chief Financial Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Bekiroglu Elizabeth — General Counsel & Corp. Sec. | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Kanesa-thasan Niranjan — Chief Medical Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Holtzman Douglas — Chief Scientific Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Cearley Cassia — Chief Business Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Simpson Adam K. — Chief Executive Officer, Director | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2023-02-16 | 4 | Simpson Adam K. — Chief Executive Officer, Director | Option exercise (M): 10,677 @ $1.04 · Option exercise (M): 10,677 (derivative) @ $0 | EDGAR |
| 2023-02-15 | 4 | Bekiroglu Elizabeth — General Counsel & Corp. Sec. | Sale (S): 5,922 @ $10.69 | EDGAR |
| 2023-02-15 | 4 | Simpson Adam K. — Chief Executive Officer, Director | Sale (S): 7,506 @ $10.69 | EDGAR |
| 2023-02-15 | 4 | Holtzman Douglas — Chief Scientific Officer | Sale (S): 1,522 @ $10.69 · Sale (S): 3,349 @ $10.17 | EDGAR |
| 2023-02-15 | 4 | Russo Thomas Joseph — Chief Financial Officer | Sale (S): 1,902 @ $10.69 | EDGAR |
| 2023-02-15 | 4 | Kanesa-thasan Niranjan — Chief Medical Officer | Sale (S): 1,794 @ $10.69 | EDGAR |
| 2023-02-15 | 4 | Cearley Cassia — Chief Business Officer | Sale (S): 1,660 @ $10.69 | EDGAR |
| 2023-01-31 | 4 | Cearley Cassia — Chief Business Officer | Option exercise (M): 25,102 @ $0.84 · Option exercise (M): 25,102 (derivative) @ $0 | EDGAR |
Recent 8-K events — Icosavax, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-02-20 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-12-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-09 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-05-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ICVX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs